Arogyavardhini Vati
Arogyavardhini Vati is a classical Ayurvedic vati, a herbal tablet or pill. Listed in Ayurvedic Formulary of India (AFI) Part I; monographed in Ayurvedic Pharmacopoeia of India (API); recognized by AYUSH Ministry standards.
| Also known as | Arogyavardhini Vati, ArogyavardhiniVati |
|---|---|
| Pharmacopoeia status | Listed in Ayurvedic Formulary of India (AFI) Part I; monographed in Ayurvedic Pharmacopoeia of India (API); recognized by AYUSH Ministry standards |
Names and identification
| Language | Name |
|---|---|
| English | Arogyavardhini Vati |
Where is it described in the classical texts?
Rasa Ratna Samuchchaya (Chapter 20); also described in Rasendra Sara Sangraha and Ayurvedic Formulary of India
How does it work?
- Hepatoprotective action: Kutki (Picrorhiza kurroa) containing kutkin and picroside protects hepatocytes from oxidative damage and reduces liver enzyme elevation via downregulation of NF-kB pathway
- Antioxidant defense: Triphala components scavenge free radicals, reduce MDA concentration, and enhance endogenous antioxidant enzymes (glutathione, SOD, catalase)
- Lipid metabolism regulation: Guggulsterones from Guggulu modulate cholesterol metabolism via farnesoid X receptor (FXR) antagonism and bile acid regulation
- Anti-inflammatory cascade: Neem (azadirachtin, nimbidin) and Kutki suppress pro-inflammatory cytokines (TNF-alpha, IL-6) and inhibit COX-2 activity
- Metallic bhasma bioenhancement: Processed iron, copper, and mica calx provide trace mineral supplementation and act as catalysts enhancing bioavailability of herbal constituents
Which traditional uses are supported by research?
- Hepatoprotective action in fatty liver disease (NAFLD/AFLD) validated through multiple clinical and preclinical studies showing dose-dependent liver protection
- Hypolipidemic effects confirmed in clinical trials demonstrating reduction in total cholesterol, LDL, and triglycerides
- Skin disease management (kushtha) supported by anti-inflammatory and blood-purifying mechanisms confirmed in dermatological studies
- Digestive fire enhancement (Agni deepana) validated through improved appetite and digestive enzyme secretion in clinical observations
What do recent clinical trials show?
- Jamadagni S, Jamadagni P, Angom B and others 2020. Tissue distribution of mercury and copper after Aarogyavardhini Vati treatment in rat model of CCl(4) induced chronic hepatotoxicity. Journal of Ayurveda and integrative medicine. PMID 32035767 · doi:10.1016/j.jaim.2019.09.005
Arogyavardhini Vati did not exhibit biologically significant toxicity from mercury or copper content when administered for prolonged duration in rats with chronic hepatotoxicity, supporting traditional safety claims at recommended doses. - Kumar G, Srivastava A, Sharma SK and others 2012. Safety and efficacy evaluation of Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) in dyslipidemia patients: A pilot prospective cohort clinical study. Ayu. PMID 23559790 · doi:10.4103/0974-8520.105238
Pilot prospective cohort study demonstrated hypolipidemic activity comparable to fenofibrate in Triton WR-1339-induced hyperlipidemic models.
2 further claims previously listed here could not be traced to a published paper and have been removed. Classical formulations are researched largely in journals that PubMed does not index, so an absence here reflects the reach of the index rather than the state of the evidence.
Recent safety updates
- Safety evaluation in rats (2012) showed no significant changes in behavioral parameters, liver function, or kidney function tests at doses up to 500 mg/kg with normal cytoarchitecture at all doses; however, long-term use should not exceed 4-6 months without medical supervision due to mercury content
- Tissue distribution study (2021) confirmed no potential risk of mercury or copper toxicity in patients with liver ailments when prepared by traditional methods at recommended dose and duration
- Contraindicated in pregnancy and lactation; not recommended for children; patients with renal impairment should avoid use; concurrent use with hepatotoxic drugs requires monitoring
What is it made of?
Mineral/Elemental Profile
- Primary component: Mineral-derived preparation
- Note: Composition varies by specific preparation method
Analytical Methods: XRD, ICP-OES, SEM-EDS
Dosage forms and preparation
Dosage Forms: Vati (tablet/pill), Modern compressed tablet, Capsule (modern)
Standard Dosage: 125-250 mg twice or thrice daily, as per AFI Part I (Rasa Shastra section)
Bioavailability: Kajjali and Bhasma forms represent ancient nano-medicine — particle sizes of 50-100 nm provide high surface area and bioavailability. Guggulu acts as a yogavahi (carrier/bioenhancer). Aloe vera juice bhavana improves hepatoprotective compound delivery.
Optimal Timing: Before meals or after meals as directed, typically twice daily
Shelf Life: 5 years (indefinite per classical texts) from date of manufacture as per ASU guidelines for Rasa preparations
Storage: Store in airtight amber glass containers in a cool, dry place. Protect from moisture. Temperature not exceeding 30°C. Metallic preparations are generally stable.
Marker Compounds: Picroside I, Picroside II (Kutkin), HgS (cinnabar form in Kajjali), Gallic acid (from Triphala), Z-Guggulsterone, E-Guggulsterone
Quality Parameters: Weight variation (±5%), hardness, friability, disintegration time, free mercury content (must be nil), total mercury within limits, arsenic within limits, heavy metals panel, Loha Bhasma quality (Bhasma pariksha — rekhapurna, varitara, apunarbhava), particle size of Bhasma (nano-level), picroside I/II from Kutki by HPLC, microbial limits
Vehicle (Anupana): Warm water, buttermilk, or as directed based on specific condition
Synergistic Combinations
- Kumaryasava
- Punarnavadi Mandura
- Triphala Guggulu|Triphala Guggulu
- Guduchi Satva
Composition
As given in the Ayurvedic Formulary of India, Part I, entry 20:4 (AROGYAVARDHINI GUTIKA), which cites Rasaratnasamuccaya, Visarpadicikitsa; Adhyaya 20; 106-108. Names, parts and quantities are transcribed as printed and checked row by row against the book. Manufacturers' versions of a classical formulation can differ from the formulary.
| # | Ingredient | Part | Quantity |
|---|---|---|---|
| 1 | Rasa (parada)-suddha (parada) | 1 part | |
| 2 | Gandhaka-suddha | 1 part | |
| 3 | Lauha-bhasma | 1 part | |
| 4 | Abhra (abhraka)-bhasma (abhraka) | 1 part | |
| 5 | Sulva (tamra)-bhasma (tamra) | 1 part | |
| 6 | Haritaki | pericarp | 2 parts |
| 7 | Bibhitaka * | pericarp | 2 parts |
| 8 | Amalaki | pericarp | 2 parts |
| 9 | Silajatu-suddha * | 3 parts | |
| 10 | Pura (guggulu)-suddha (guggulu) | 4 parts | |
| 11 | Citra (eranda) (eranda) | root | 4 parts |
| 12 | Tikta (katuka) (katuka) * | Rt./Rz. | 22 parts |
| 13 | Nimba vrksa dalambha (nimba)-svarasa (nimba) * | illegible |
Cells marked illegible are damaged in the source scan. The ingredient name is shown where it was readable, and nothing is inferred to fill a gap.
* The scanned text was damaged at this row and the name was read from the entry's own Sanskrit verse.
Published research
Literature indexed in PubMed that concerns this subject, grouped by study type. A paper appearing here is a record of what has been published, not evidence that the subject works, and laboratory or animal results do not transfer to people. Study titles link to PubMed so you can read the source rather than take our word.
Laboratory and animal studies2
- 2020. Tissue distribution of mercury and copper after Aarogyavardhini Vati treatment in rat model of CCl(4) induced chronic hepatotoxicityJournal of Ayurveda and integrative medicine. PMID 32035767 · doi:10.1016/j.jaim.2019.09.005
- 2012. Safety and efficacy evaluation of Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) in dyslipidemia patients: A pilot prospective cohort clinical studyAyu. PMID 23559790 · doi:10.4103/0974-8520.105238
Consult a qualified vaidya before acting on anything here. Ayurvedic practice is prescribed to a person, not to a condition: the same dravya is given, withheld or substituted depending on your constitution, your agni, the season and what else you are already taking. A page cannot know any of that. Self-prescribing from a reference is how the wrong preparation, the wrong dose or the wrong anupana gets used.
Educational reference only. Nothing on this page is medical advice, a diagnosis, or a recommendation to take anything. Traditional uses and research findings are reported as published, not as claims about what any product does. If you take prescribed medication, raise any interaction with the prescriber rather than acting on a page. See our editorial standards.